Search CTL/CD8+ T-Cell Epitope Database

Found 9 matching records:

Displaying record number 54625

HXB2 Location	Gag(162-172) p24(30-40) DNA(1273..1305)	Gag Epitope Map
Author Location	Gag
Epitope	`KAFSPEVIPMF`	Epitope Alignment
		Show epitope variants
Epitope Name	KF11
Subtype	C
Species (MHC/HLA)	human(B5701, B5703)
Immunogen	HIV-1 infection
Country	South Africa
Experimental methods	CD8 T-cell Elispot - IFNγ
Keywords	rate of progression, escape, HLA associated polymorphism, elite controllers

Notes

To study whether CTL responses restricted by "good" HLA I molecules exert stronger immune selection than other HLA I molecules, 54 and 70 optimal epitopes within HIV-1 Gag, Pol and Nef genes for Caucasian and African cohorts were tested in patients over a mean of 14 months. "Good", advantageous HLA allele-restricted epitopes were much more polymorphic than epitopes restricted by other, non-advantageous HLA in patients, suggesting that benefits associated with HLA Class I alleles of elite controllers of disease progression are epitope-specific. Such "driver" epitopes with high polymorphism had high frequency of immune response, allowing them to be ranked for recognition and polymorphism.
Patients with higher proportions of mutated epitopes also had lower plasma viral loads, and mean epitope variability correlated negatively with relative hazard of disease progression.
This Gag epitope KF11 is highly variant in the African cohort when restricted by B*5703, but is conserved in the Caucasian B*5701-positive cohort.

References

Frater2007 A. J. Frater, H. Brown, A. Oxenius, H. F. Günthard, B. Hirschel, N. Robinson, A. J. Leslie, R. Payne, H. Crawford, A. Prendergast, C. Brander, P. Kiepiela, B. D. Walker, P. J. R. Goulder, A. McLean, and R. E. Phillips. Effective T-Cell Responses Select Human Immunodeficiency Virus Mutants and Slow Disease Progression. J. Virol., 81(12):6742-6751, Jun 2007. PubMed ID: 17409157. Show all entries for this paper.

Displaying record number 54622

HXB2 Location	Gag(180-188) p24(48-56) DNA(1327..1353)	Gag Epitope Map
Author Location	Gag
Epitope	`TPQDLNTML`	Epitope Alignment
		Show epitope variants
Epitope Name	TL9
Subtype	C
Species (MHC/HLA)	human(B*8101)
Immunogen	HIV-1 infection
Country	South Africa
Experimental methods	CD8 T-cell Elispot - IFNγ
Keywords	rate of progression, escape, HLA associated polymorphism, elite controllers

Notes

To study whether CTL responses restricted by "good" HLA I molecules exert stronger immune selection than other HLA I molecules, 54 and 70 optimal epitopes within HIV-1 Gag, Pol and Nef genes for Caucasian and African cohorts were tested in patients over a mean of 14 months. "Good", advantageous HLA allele-restricted epitopes were much more polymorphic than epitopes restricted by other, non-advantageous HLA in patients, suggesting that benefits associated with HLA Class I alleles of elite controllers of disease progression are epitope-specific. Such "driver" epitopes with high polymorphism had high frequency of immune response, allowing them to be ranked for recognition and polymorphism.
Patients with higher proportions of mutated epitopes also had lower plasma viral loads, and mean epitope variability correlated negatively with relative hazard of disease progression.
Variants TPsDLNTML and TPQDLNsML at positions 3 and 7 were the predominant polymorphisms found.

References

Displaying record number 54619

HXB2 Location	Gag(240-249) p24(108-117) DNA(1507..1536)	Gag Epitope Map
Author Location	p24(108-117)
Epitope	`TSTLQEQIGW`	Epitope Alignment
		Show epitope variants
Epitope Name	TW10
Subtype	B
Species (MHC/HLA)	human(B57, B58)
Immunogen	HIV-1 infection
Country	Switzerland
Experimental methods	CD8 T-cell Elispot - IFNγ
Keywords	rate of progression, escape, viral fitness and reversion, HLA associated polymorphism, elite controllers

Notes

To study whether CTL responses restricted by "good" HLA I molecules exert stronger immune selection than other HLA I molecules, 54 and 70 optimal epitopes within HIV-1 Gag, Pol and Nef genes for Caucasian and African cohorts were tested in patients over a mean of 14 months. "Good", advantageous HLA allele-restricted epitopes were much more polymorphic than epitopes restricted by other, non-advantageous HLA in patients, suggesting that benefits associated with HLA Class I alleles of elite controllers of disease progression are epitope-specific. Such "driver" epitopes with high polymorphism had high frequency of immune response, allowing them to be ranked for recognition and polymorphism.
Patients with higher proportions of mutated epitopes also had lower plasma viral loads, and mean epitope variability correlated negatively with relative hazard of disease progression.
Variants TSnLQEQIGW and TSTLQEQIaW at positions 3 and 9, were present in 86.7% of HLA-matched patients and 28.3% of HLA-unmatched patients. Phylogenetic analysis identified the threonine at position 3 to be under strong positive selective pressure.

References

Displaying record number 54621

HXB2 Location	Gag(240-249) p24(108-117) DNA(1507..1536)	Gag Epitope Map
Author Location	Gag
Epitope	`TSTLQEQIAW`	Epitope Alignment
		Show epitope variants
Epitope Name	TW10
Subtype	C
Species (MHC/HLA)	human(B5703, B5801)
Immunogen	HIV-1 infection
Country	South Africa
Experimental methods	CD8 T-cell Elispot - IFNγ, Other
Keywords	rate of progression, escape, HLA associated polymorphism, elite controllers

Notes

To study whether CTL responses restricted by "good" HLA I molecules exert stronger immune selection than other HLA I molecules, 54 and 70 optimal epitopes within HIV-1 Gag, Pol and Nef genes for Caucasian and African cohorts were tested in patients over a mean of 14 months. "Good", advantageous HLA allele-restricted epitopes were much more polymorphic than epitopes restricted by other, non-advantageous HLA in patients, suggesting that benefits associated with HLA Class I alleles of elite controllers of disease progression are epitope-specific. Such "driver" epitopes with high polymorphism had high frequency of immune response, allowing them to be ranked for recognition and polymorphism.
Patients with higher proportions of mutated epitopes also had lower plasma viral loads, and mean epitope variability correlated negatively with relative hazard of disease progression.
Variant TSnLQEQIGW at position 3 was often found in conjunction with a second polymorphism at positions 5, 8 or 9.

References

Displaying record number 54618

HXB2 Location	Gag(263-272) p24(131-140) DNA(1576..1605)	Gag Epitope Map
Author Location	p24(131-140)
Epitope	`KRWIILGLNK`	Epitope Alignment
		Show epitope variants
Epitope Name	KK10
Subtype	B
Species (MHC/HLA)	human(B*27)
Immunogen	HIV-1 infection
Country	Switzerland
Experimental methods	CD8 T-cell Elispot - IFNγ
Keywords	rate of progression, escape, HLA associated polymorphism, elite controllers

Notes

To study whether CTL responses restricted by "good" HLA I molecules exert stronger immune selection than other HLA I molecules, 54 and 70 optimal epitopes within HIV-1 Gag, Pol and Nef genes for Caucasian and African cohorts were tested in patients over a mean of 14 months. "Good", advantageous HLA allele-restricted epitopes were much more polymorphic than epitopes restricted by other, non-advantageous HLA in patients, suggesting that benefits associated with HLA Class I alleles of elite controllers of disease progression are epitope-specific. Such "driver" epitopes with high polymorphism had high frequency of immune response, allowing them to be ranked for recognition and polymorphism.
Patients with higher proportions of mutated epitopes also had lower plasma viral loads, and mean epitope variability correlated negatively with relative hazard of disease progression.
Variants KkWIILGLNK and KRWIImGLNK/KRWIIiGLNK at positions 2 and 6 were found. Phylogenetic analysis identified the leucine at position 6 to be under strong positive selective pressure.

References

Displaying record number 54623

HXB2 Location	Pol(158-167) RT(3-12) DNA(2556..2585)	Pol Epitope Map
Author Location	Pol
Epitope	`SPIETVPVKL`	Epitope Alignment
		Show epitope variants
Epitope Name	SL10
Subtype	C
Species (MHC/HLA)	human(B*8101)
Immunogen	HIV-1 infection
Country	South Africa
Experimental methods	CD8 T-cell Elispot - IFNγ
Keywords	rate of progression, escape, HLA associated polymorphism, elite controllers

Notes

To study whether CTL responses restricted by "good" HLA I molecules exert stronger immune selection than other HLA I molecules, 54 and 70 optimal epitopes within HIV-1 Gag, Pol and Nef genes for Caucasian and African cohorts were tested in patients over a mean of 14 months. "Good", advantageous HLA allele-restricted epitopes were much more polymorphic than epitopes restricted by other, non-advantageous HLA in patients, suggesting that benefits associated with HLA Class I alleles of elite controllers of disease progression are epitope-specific. Such "driver" epitopes with high polymorphism had high frequency of immune response, allowing them to be ranked for recognition and polymorphism.
Patients with higher proportions of mutated epitopes also had lower plasma viral loads, and mean epitope variability correlated negatively with relative hazard of disease progression.
Variants SsIETVPVKL and SPIkTVPVKL at positions 2 and 4 were the predominant polymorphisms found.

References

Displaying record number 54617

HXB2 Location	Pol(283-290) RT(128-135) DNA(2931..2954)	Pol Epitope Map
Author Location	Pol
Epitope	`TAFTIPSI`	Epitope Alignment
		Show epitope variants
Epitope Name	TI8
Subtype	B
Species (MHC/HLA)	human(B*51)
Immunogen	HIV-1 infection
Country	Switzerland
Experimental methods	CD8 T-cell Elispot - IFNγ
Keywords	rate of progression, escape, HLA associated polymorphism, elite controllers

Notes

To study whether CTL responses restricted by "good" HLA I molecules exert stronger immune selection than other HLA I molecules, 54 and 70 optimal epitopes within HIV-1 Gag, Pol and Nef genes for Caucasian and African cohorts were tested in patients over a mean of 14 months. "Good", advantageous HLA allele-restricted epitopes were much more polymorphic than epitopes restricted by other, non-advantageous HLA in patients, suggesting that benefits associated with HLA Class I alleles of elite controllers of disease progression are epitope-specific. Such "driver" epitopes with high polymorphism had high frequency of immune response, allowing them to be ranked for recognition and polymorphism.
Patients with higher proportions of mutated epitopes also had lower plasma viral loads, and mean epitope variability correlated negatively with relative hazard of disease progression.
TAFTIPSI escapes very soon after seroconversion to the variant TAFTIPSt with change at its carboxyl terminus, position 8, which has been identified by phylogenetic analysis to be under strong positive selection pressure. It was present in 7/8 of HLA-matched patients and 21/57 of HLA-unmatched patients.

References

Displaying record number 54624

HXB2 Location	Nef(71-79) DNA(9007..9033)	Nef Epitope Map
Author Location	Nef
Epitope	`RPQVPLRPM`	Epitope Alignment
		Show epitope variants
Epitope Name	RM9
Subtype	C
Species (MHC/HLA)	human(B*8101)
Immunogen	HIV-1 infection
Country	South Africa
Experimental methods	CD8 T-cell Elispot - IFNγ
Keywords	rate of progression, escape, HLA associated polymorphism, elite controllers

Notes

To study whether CTL responses restricted by "good" HLA I molecules exert stronger immune selection than other HLA I molecules, 54 and 70 optimal epitopes within HIV-1 Gag, Pol and Nef genes for Caucasian and African cohorts were tested in patients over a mean of 14 months. "Good", advantageous HLA allele-restricted epitopes were much more polymorphic than epitopes restricted by other, non-advantageous HLA in patients, suggesting that benefits associated with HLA Class I alleles of elite controllers of disease progression are epitope-specific. Such "driver" epitopes with high polymorphism had high frequency of immune response, allowing them to be ranked for recognition and polymorphism.
Patients with higher proportions of mutated epitopes also had lower plasma viral loads, and mean epitope variability correlated negatively with relative hazard of disease progression.
Variant RPQVPvRPM at position 6 was the predominant polymorphism found.

References

Displaying record number 54620

HXB2 Location	Nef(116-125) DNA(9142..9171)	Nef Epitope Map
Author Location	Nef(116-125)
Epitope	`HTQGYFPDWQ`	Epitope Alignment
		Show epitope variants
Epitope Name	HQ10
Subtype	B
Species (MHC/HLA)	human(B*57)
Immunogen	HIV-1 infection
Country	Switzerland
Experimental methods	CD8 T-cell Elispot - IFNγ
Keywords	rate of progression, escape, HLA associated polymorphism, elite controllers

Notes

To study whether CTL responses restricted by "good" HLA I molecules exert stronger immune selection than other HLA I molecules, 54 and 70 optimal epitopes within HIV-1 Gag, Pol and Nef genes for Caucasian and African cohorts were tested in patients over a mean of 14 months. "Good", advantageous HLA allele-restricted epitopes were much more polymorphic than epitopes restricted by other, non-advantageous HLA in patients, suggesting that benefits associated with HLA Class I alleles of elite controllers of disease progression are epitope-specific. Such "driver" epitopes with high polymorphism had high frequency of immune response, allowing them to be ranked for recognition and polymorphism.
Patients with higher proportions of mutated epitopes also had lower plasma viral loads, and mean epitope variability correlated negatively with relative hazard of disease progression.
Variant nTQGYFPDWQ at position 1 was found in 100% of HLA-matched patients and in 28.8% of HLA-unmatched patients.